Frazier Life Sciences Management L.P. Has $22.08 Million Stock Holdings in Merus (NASDAQ:MRUS)

Frazier Life Sciences Management L.P. lessened its stake in shares of Merus (NASDAQ:MRUS) by 50.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 373,100 shares of the biotechnology company’s stock after selling 373,379 shares during the period. Merus accounts for 1.0% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 25th largest holding. Frazier Life Sciences Management L.P. owned 0.64% of Merus worth $22,076,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRUS. Allspring Global Investments Holdings LLC acquired a new stake in shares of Merus in the first quarter worth $72,000. SG Americas Securities LLC bought a new position in Merus in the first quarter worth $108,000. Sierra Summit Advisors LLC bought a new position in Merus in the fourth quarter worth $221,000. Farallon Capital Management LLC bought a new position in shares of Merus during the second quarter valued at $237,000. Finally, ProShare Advisors LLC bought a new position in shares of Merus during the second quarter valued at $242,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Lifesci Capital raised Merus to a “strong-buy” rating in a report on Monday, July 29th. Canaccord Genuity Group raised Merus to a “strong-buy” rating in a report on Thursday, July 25th. Stifel Nicolaus lifted their price objective on Merus from $90.00 to $99.00 and gave the company a “buy” rating in a report on Monday, June 17th. Truist Financial lifted their price objective on Merus from $69.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. Finally, Citigroup lifted their price objective on Merus from $70.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday, June 26th. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $80.20.

Merus Stock Up 1.2 %

Shares of NASDAQ MRUS opened at $47.74 on Friday. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -17.23 and a beta of 1.12. Merus has a 12-month low of $19.81 and a 12-month high of $61.61. The firm’s 50-day simple moving average is $51.29 and its 200 day simple moving average is $49.95.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.05). The firm had revenue of $7.33 million for the quarter, compared to the consensus estimate of $9.64 million. Merus had a negative return on equity of 36.33% and a negative net margin of 476.41%. On average, equities analysts expect that Merus will post -3.27 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.